8-K: KORU Medical Systems Reports Strong Q3 2026 Results

KORU Medical Systems announced robust third quarter 2026 financial results, featuring an 11% revenue increase and second consecutive quarter of positive net income and Adjusted EBITDA.

Summary

• KORU Medical Systems reported third quarter 2026 net revenues of $11.6 million, an 11.2% increase year-over-year.
• Gross profit rose 20.5% to $7.5 million, with gross margin improving to 65.2% from 60.2% in the prior year period.
• The company achieved a net income of $0.2 million ($0.00 per diluted share), a significant improvement from a net loss of $0.8 million ($0.02 per diluted share) in the prior year.
• Adjusted EBITDA increased to $1.3 million from $0.1 million in the prior year period.
• Full-year 2026 revenue guidance has been revised upwards to $48.0 $48.5 million, representing 17%-18% year-over-year growth.
• Full-year 2026 gross margin guidance is now projected between 63% 64%.
• Cash and cash equivalents stood at $7.4 million as of September 30, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, with the company demonstrating sequential improvement and exceeding previous guidance in key areas.

Positives

• Net revenues grew 11.2% to $11.6 million in Q3 2026.
• Gross profit increased by 20.5% to $7.5 million.
• Gross margin improved to 65.2% from 60.2% due to lower manufacturing costs, higher selling prices, and tariff rebates.
• Achieved positive net income of $0.2 million, a $1.0 million improvement from the prior year's net loss.
• Achieved positive Adjusted EBITDA of $1.3 million, a significant increase from $0.1 million in the prior year.
• Revised full-year 2026 revenue guidance upwards to $48.0 $48.5 million.
• Revised full-year 2026 gross margin guidance upwards to 63% 64%.
• Signed two new sales and distribution agreements in Europe and Africa.

Negatives

• International core revenues decreased by 16.5% to $3.1 million, primarily due to a higher prior-year comparison base and distributor purchasing patterns.
• Pharma services and clinical trials net revenues decreased by 27.4% to $0.4 million.
• Cash and cash equivalents decreased by $0.9 million in the third quarter of 2026.

Risks

• Uncertainties associated with inflation, tariffs, war, and other geopolitical conflicts.
• Customer ordering patterns and availability and costs of raw materials and labor.
• Compliance with Food and Drug Administration and foreign authority regulations and the outcome of regulatory audits.
• Introduction and adoption of competitive products.
• Acceptance of and demand for new and existing products.
• Ability to penetrate new markets.
• Success in enforcing and obtaining patents.
• Reimbursement related risks and government regulation of the home health care industry.

Future Outlook

The company is revising its full-year 2026 revenue guidance to $48.0 $48.5 million, representing 17%-18% year-over-year growth. Full-year 2026 gross margin is projected to be between 63% 64%. The company reiterates its expectation of positive adjusted EBITDA for the full year and anticipates a year-end cash balance greater than $8.0 million. Management expects revenue growth to reaccelerate in the fourth quarter.

Management Comments

• Total Revenue of $11.6 million represents another quarter of consistent above-market growth for KORU, driven by our recurring patient base.
• We also delivered positive net income and adjusted EBITDA for the second consecutive quarter, demonstrating the scalability of our business model.
• As anticipated, our year-over-year revenue growth moderated in the third quarter compared to the first half of 2026, reflecting in part the timing of our entry into a competitive non-tender market in Europe.
• With that market launch now behind us, we anticipate revenue growth to reaccelerate in the fourth quarter for a strong finish to the year.
• We are encouraged by our geographic expansion, specialty pharmacy partnerships, and pipeline advancements and plan to continue investing resources in our long-term growth strategy as we move forward.

Industry Context

StockSavvy.ai notes that KORU Medical Systems operates in the medical technology sector, specifically focusing on infusion solutions. The reported revenue growth and margin improvement align with a trend of increasing demand for specialized medical devices, particularly those that enhance patient quality of life and facilitate home-based care. The company's international expansion efforts are also a common strategy for growth in this industry.

Comparison to Industry Standards

• The reported 11.2% year-over-year revenue growth for Q3 2026 is strong, especially within the medical device sector where growth rates can vary significantly by sub-segment.
• The improvement in gross margin to 65.2% is a positive indicator of operational efficiency and pricing power, which is generally considered a benchmark of a healthy business in the medical technology space.
• Achieving positive net income and Adjusted EBITDA for the second consecutive quarter suggests a positive trajectory towards sustainable profitability, a key metric investors look for.
• The upward revision of full-year revenue guidance indicates that KORU Medical is outperforming its initial expectations and potentially the broader industry average for its niche.

Stakeholder Impact

• Shareholders: Potential for increased stock value due to improved financial performance and upward revised guidance.
• Customers: Continued access to innovative infusion solutions, with potential for expanded geographic availability.
• Employees: Positive financial results may support continued investment in headcount and development.
• Suppliers: Increased demand for products may lead to sustained or increased orders.

Next Steps

• Continue investing resources in long-term growth strategy.
• Focus on geographic expansion, specialty pharmacy partnerships, and pipeline advancements.
• Anticipate revenue growth to reaccelerate in the fourth quarter for a strong finish to the year.

Key Dates

Recommendation

The company is showing positive momentum with improved profitability and upward revised guidance. However, the decrease in international revenue and the reliance on non-GAAP measures warrant a cautious approach. While the trend is positive, further sustained performance and clarity on international market dynamics are needed for a stronger buy recommendation. A 'hold' reflects the current positive trajectory balanced with the need for continued monitoring.

Keywords

medical technology, infusion solutions, subcutaneous infusion, revenue growth, profitability, EBITDA, gross margin, guidance